Proteins in Outer Membrane Vesicles Produced by *Burkholderia cepacia* are Responsible for Pro-inflammatory Responses in Epithelial Cells

Se Yeon Kim¹, Seung Il Kim²,³, Sung Ho Yun², Minsang Shin¹, Yoo Chul Lee¹, Je Chul Lee¹*  
¹Department of Microbiology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea  
²Drug & Disease Target Team, Korea Basic Science Institute, Ochang 28119, Republic of Korea  
³Department of Bio-Analytical Science, University of Science and Technology (UST), Daejeon 34116, Republic of Korea

INTRODUCTION

*Burkholderia cepacia* is a member of *B. cepacia* complex (BCC) that is a group of catalase-positive, lactose non-fermenting, gram-negative bacteria comprised of at least 20 different species, including *B. cepacia*, *B. multivorans*, *B. cenocepacia*, *B. vietnamiensis*, *B. stabilis*, *B. ambifaria*, *B. dolosa*, *B. anthina*, and *B. pyrrocinia* (1, 2). *B. cenocepacia* and *B. multivorans* are the most frequently isolated from the patients with cystic fibrosis belonging to the BCC (3, 4). *B. cepacia* has also emerged as an important human pathogen, especially in healthcare settings, although this microorganism was first discovered as a causative agent of onion skin rot (5, 6). BCC bacteria, including *B. cepacia*, pose little medical risk to healthy people, but the patients with underlying diseases such as chronic granulomatous
diseases, chronic lung diseases or hematologic malignancies are susceptible to BCC infection (4, 7). BCC exhibits a relatively low virulence, but produces several virulence-associated determinants, including elastases, gelatinases, hemolysins, lipases, proteases, and siderophores, have been determined, which may play a role in colonization and infection in the hosts and survival of bacteria in environment (8-10). However, secretomes associated with bacterial pathogenesis have not been fully characterized.

All gram-negative bacteria produce and secrete outer membrane vesicles (OMVs) sized with 20-300 nm (11). OMVs are a secreted cargo that transports toxins, virulence factors, and other bacterial molecules to the host cells and can modulate physiology of host cells (12, 13). Gram-negative bacterial pathogens, including Escherichia coli (14), Pseudomonas aeruginosa (15), Acinetobacter baumannii (16), A. nosocomialis (17), Stenotrophomonas maltophilia (18), and BCC (19), secrete OMVs during in vitro culture and the secreted OMVs induce host cell cytotoxicity and pro-inflammatory responses. We recently demonstrated that B. cepacia ATCC 25416 and two clinical isolates secreted OMVs during in vitro culture (20). Moreover, B. cepacia ATCC 25416 produced more OMVs under antibiotic stress conditions such as sub-minimum inhibitory concentrations of ceftazidime, meropenem, and trimethoprim/sulfamethoxazole, than under antibiotic-free conditions. OMVs isolated from B. cepacia cultured under antibiotic stress conditions induced significantly higher pro-inflammatory responses in lung epithelial A549 cells than OMVs from B. cepacia cultured under antibiotic-free conditions. However, bacterial molecules associated with the cytotoxicity or pro-inflammatory responses in B. cepacia OMVs have not been determined. The aim of this study was to analyze the proteomes of OMVs produced by B. cepacia and investigate their contribution to the induction of host cell cytotoxicity and pro-inflammatory responses in vitro.

MATERIALS AND METHODS

Bacterial strain and cell culture

B. cepacia ATCC 25416 was purchased from the American Type Culture Collection (Manassas, VA, USA). Bacteria were cultured in lysogeny (LB) broth with shaking at 37°C. A549 cells originated from human lung epithelial cells were purchased from the Korean Cell Line Bank (Seoul, Korea). A549 cells were grown in RPMI 1640 medium (HyClone, Logan, UT, USA) supplemented with 10% heat-inactivated fetal bovine serum (HyClone), 2 mM L-glutamine, and 1,000 U/mL penicillin G 37°C in a humidified atmosphere with 5% CO₂. Cells were seeded in 6- and 96-well plates for the cytokine gene expression and cell viability assays, respectively.

Isolation of OMVs

The OMVs of B. cepacia ATCC 25416 were purified from bacterial culture supernatants as previously described (20, 21). Bacteria were cultured to 1.5 optical density at A600 (OD₆₀₀) in 1 L of LB broth with shaking at 37°C. Bacterial culture was centrifuged at 8,000 g for 20 min at 4°C and supernatants were filtered using a bottle-top filter with a 0.22 μm membrane. The filtered supernatant samples were concentrated using a QuixStand Benchtop System (GE Healthcare, Amersham, UK) with a 500 kDa hollow fiber membrane (GE Healthcare). OMVs were collected by ultracentrifugation at 150,000 g for 3 h at 4°C and then washed in phosphate-buffered saline (PBS) followed by another ultracentrifugation cycle. OMV pellets were resuspended in 100-200 μl of PBS. The protein concentration of OMVs was determined using a modified BCA assay (Thermo Scientific, Waltham, MA, USA). The purified OMVs were streaked on blood agar plates to check for sterility and then stored at -80°C until use. B. cepacia OMVs were treated with 0.1 μg/ml proteinase K (Fermentas, St. Leon-Rot, Germany) for 3 h at 50°C for the degradation of OMV proteins (22).
Proteins in *B. cepacia* OMVs were identified using one-dimensional gel electrophoresis and liquid chromatography-tandem mass spectrometry (1-DE-LC-MS/MS) as previously described (23, 24). Proteins of OMVs (15 μg) were separated on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and divided into eight fractions according to molecular weight. In-gel digestion was performed as previously described (24). Tryptic peptide mixtures were recovered after tryptic digestion, and the peptide extracts were pooled and lyophilized. Peptide samples were then concentrated on a 2G-V/V trap column (Waters, Milford, MA, USA), and concentrated peptides were eluted into a 10 cm × 75 μm (i.d.) C18 reversed-phase column at a flow rate of 300 nl/min. High performance liquid chromatography conditions and search parameters for tandem mass spectrometry (MS/MS) analysis were applied. All MS and MS/MS spectra were acquired using an LTQ-Velos ESI ion trap mass spectrometer in data-dependent mode. For protein identification, nano-LC-MS/MS spectra were searched using MASCOT version 2.4 (Matrix Science, UK) with protein sequences obtained from the *B. cepacia* ATCC 25416 genome. A proteomic analysis was performed in triplicate with different samples, and proteins identified in all three experiments were analyzed. Locations of proteins were predicted using the subcellular location prediction program, CELLO version 2.5 (http://cello.life.nctu.edu.tw/). The exponentially modified protein abundance index (emPAI) and mol% were acquired using MASCOT software (25). Proteins identified in *B. cepacia* OMVs were classified according to Gene Ontology (GO) functions using Blast2Go Pro software (https://www.blast2go.com/).

**Cell viability**

Cell viability was measured using the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT) assay (Abcam, Cambridge, UK). A549 cells were seeded at a concentration of 2.0 × 10^4/well in a 96-well microplate. Cells were incubated with either intact *B. cepacia* OMVs or proteinase K-treated OMVs for 24 h and then cell viability was measured 2 h after treatment with MTT reagent at 600 nm.

**Quantitative real-time polymerase chain reaction (qPCR) of cytokine genes**

A549 cells cultured in 6-well plates were incubated with 0, 10, and 20 μg/ml of intact *B. cepacia* OMVs or proteinase K-treated OMVs for 6 h. Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. cDNA was synthesized by the reverse transcription of 2 μg of total RNA using oligo dT primers and TOPscript™ reverse transcriptase (Enzymomics, Daejeon, Korea) in a total reaction volume of 20 μl. qPCR was performed to determine the expression levels of genes encoding glyceraldehyde 3-phosphate dehydrogenase (GAPDH), interleukin (IL) 1B, IL6, IL8, tumor necrosis factor (TNF), and C-C motif chemokine ligand 2 (CCL2) as previously described (26, 27). Quantification of the gene transcripts was performed using a StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) with TOPreal™ qPCR 2X PreMIX (SYBR Green with high ROX) (Enzymomics) according to the manufacturer’s instructions. The amplification specificity was evaluated using melting curve analysis. Gene expression was normalized to GAPDH expression in each sample, and the fold change was determined using the ΔΔCt method. Each experiment was performed in triplicate.

**Data analysis and statistics**

Cell death and cytokine gene expression between intact OMVs and proteinase K-treated OMVs were analyzed using Student’s t-test. Differences of *P* < 0.05 were considered statistically significant.
RESULTS

Proteomes of *B. cepacia* OMVs

*B. cepacia* ATCC 25416 was cultured in LB broth and then OMVs were isolated from the culture supernatant. A proteomic analysis of *B. cepacia* OMVs was performed using 1-DE-LC-MS/MS. A total of 265 proteins were identified in OMVs isolated from *B. cepacia* ATCC 25416 cultured in LB broth. The most abundant 30 OMV proteins analyzed by emPAI and mol% were presented in Table 1. Of the 265 proteins, 179 (67.5%), 32 (12.1%), 27 (10.2%), 17 (6.4%), and 10 (3.8%) were predicted to be located in the cytoplasm, inner membrane, periplasmic space, outer membrane, and extracellular compartment, respectively (Fig. 1A). A total of 168 proteins identified in the *B. cepacia* OMVs were classified into 19 groups.

Table 1. Major proteins identified in the outer membrane vesicles derived from *B. cepacia* ATCC 25416 using 1-DE-LC-MS/MS analysis

| No | Protein name                              | Accession No.     | MW (Da)  | Gene ID       | Cellular localization |
|----|-------------------------------------------|-------------------|----------|---------------|-----------------------|
| 1  | OmpW family protein                       | WP_027787296.1    | 22,576   | CEQ23_20595   | Outer membrane        |
| 2  | Gram-negative porin family protein        | WP_027789407.1    | 37,596   | DM41_6493     | Outer membrane        |
| 3  | OmpA family protein                       | WP_021157465.1    | 23,939   | DM41_2287     | Outer membrane        |
| 4  | 60 kDa chaperonin                         | WP_021163332.1    | 57,001   | *groL*        | Cytoplasm             |
| 5  | Hypothetical protein                      | WP_080982090.1    | 10,054   |               | Cytoplasm             |
| 6  | 30S ribosomal protein S12                 | WP_006400662.1    | 13,991   | *rpsL*        | Cytoplasm             |
| 7  | Hypothetical protein                      | WP_080982195.1    | 7,153    |               | Cytoplasm             |
| 8  | DUF1289 domain-containing protein         | WP_027789832.1    | 7,149    |               | Cytoplasm             |
| 9  | Hypothetical protein                      | WP_027790335.1    | 23,396   | CEQ23_37995   | Cytoplasm             |
| 10 | Glycine zipper 2TM domain protein         | WP_021161893.1    | 15,363   | DM41_1814     | Extracellular          |
| 11 | CsbD family protein                       | WP_021162617.1    | 7,491    | CEQ23_34605   | Cytoplasm             |
| 12 | Cold-shock' DNA-binding domain protein    | WP_006483056.1    | 7,290    | DM41_6114     | Cytoplasm             |
| 13 | Hypothetical protein                      | WP_081040778.1    | 8,232    |               | Cytoplasm             |
| 14 | Type-1 fimbrial protein, A chain          | WP_027787455.1    | 17,243   | *fimA*        | Extracellular          |
| 15 | Bacterial regulatory s, luxR family protein | WP_057056468.1   | 8,938    | DM41_5655     | Cytoplasm             |
| 16 | Flagellin                                 | WP_021161125.1    | 38,736   | DM41_1448     | Extracellular          |
| 17 | Hypothetical protein                      | WP_011352325.1    | 19,742   | DM41_3403     | Extracellular          |
| 18 | DUF3562 domain-containing protein         | WP_027791570.1    | 9,642    | CEQ23_29815   | Cytoplasm             |
| 19 | Hypothetical protein                      | WP_027792032.1    | 9,617    | DM41_6990     | Cytoplasm             |
| 20 | Hypothetical protein                      | WP_027790331.1    | 20,547   | CEQ23_37970   | Cytoplasm             |
| 21 | TPR repeat family protein                 | WP_027788515.1    | 22,070   | DM41_1686     | Periplasm             |
| 22 | DUF883 domain-containing protein          | WP_006494044.1    | 10,823   | DM41_2044     | Cytoplasm             |
| 23 | Flagellar Flt family protein              | WP_027788658.1    | 10,710   | DM41_1446     | Cytoplasmic            |
| 24 | Hypothetical protein                      | WP_027786881.1    | 23,218   | CEQ23_17695   | Periplasm             |
| 25 | H-NS histone family protein               | WP_021160271.1    | 11,057   | DM41_6992     | Periplasm             |
| 26 | Cytochrome c family protein               | WP_027790167.1    | 23,519   | DM41_4337     | Cytoplasm             |
| 27 | Hypothetical protein                      | WP_027787567.1    | 11,647   | DM41_2931     | Cytoplasm             |
| 28 | Hypothetical protein                      | WP_027791579.1    | 11,467   | DM41_5965     | Periplasm             |
| 29 | Hypothetical protein                      | WP_063623143.1    | 11,709   | CEQ23_22510   | Periplasm             |
| 30 | ATP-dependent protease ATPase subunit HslU | WP_027788872.1   | 49,850   | *hslU*        | Cytoplasm             |
Proteomes of *B. cepacia* OMVs

SY Kim, et al.

based on GO functions; biosynthetic process-associated proteins (*n* = 51) were the most common category (Fig. 1B). However, 97 proteins could not be classified into a particular functional group, due to poor characterization. Several putative virulence-associated proteins, including phosphocholine-specific phospholipase C (WP_027788973.1), ATP-dependent protease HslU (WP_027788872.1), ATP-dependent zinc metalloprotease FtsH (WP_021163358.1), and ATP-dependent Clp protease (WP_027786662.1), were identified in OMVs. These results indicate that *B. cepacia* OMVs present a diverse protein profile comprising molecules derived from the cytoplasm, membrane, and extracellular compartment.

Fig. 1. Proteomic analysis of OMVs isolated from *B. cepacia* ATCC 25416. Bacterial were cultured in LB broth and OMVs were isolated from culture supernatants. Proteomic analysis was performed using 1-DE-LC-MS/MS. Locations of proteins were predicted using the subcellular location prediction program, CELLO version 2.5 (http://cello.life.nctu.edu.tw/). Proteins identified in *B. cepacia* OMVs were classified according to Gene Ontology (GO) functions using Blast2Go Pro software (https://www.blast2go.com/). A total of 265 proteins were analyzed by cellular localization (A) and GO (B).

Fig. 2. Host cell responses to proteinase K (PK)-treated *B. cepacia* OMVs. OMVs were isolated from the culture supernatants of *B. cepacia* cultured in LB. OMVs were treated with 0.1 μg/mL proteinase K for 3 h at 50°C for the degradation of OMV proteins. A549 cells were treated with either intact OMVs or PK-treated OMVs. (A) Cells were treated with 20 μg/mL OMVs for 24 h and cell viability was determined using MTT assay. Data are presented as mean ± SD of three independent experiments. (B) Cells were treated with various concentrations of OMVs for 6 h, and gene expression was assessed by qPCR. Data are presented as mean ± SD of three independent experiments. *P < 0.05, **P < 0.01 compared to intact OMVs.
Induction of pro-inflammatory response to proteins derived from \textit{B. cepacia} OMVs

We previously showed that OMVs from \textit{B. cepacia} ATCC 25416 induced host cell cytotoxicity and pro-inflammatory responses in A549 cells \textit{in vitro} (20). To determine whether proteins in OMVs were directly responsible for cytotoxicity and pro-inflammatory responses, OMVs were treated with proteinase K and then A549 cells were incubated with either intact OMVs or proteinase K-treated OMVs. Cell death was not different between intact and proteinase K-treated OMVs (Fig. 2A); however, the proteinase K-treated OMVs did not stimulate the expression of pro-inflammatory cytokine genes \textit{IL1B} and \textit{IL6}, nor the chemokine genes \textit{IL8} and \textit{CCL2} (Fig. 2B). The expression of the \textit{TNF} gene was significantly different between intact and proteinase K-treated OMVs at 10 μg/ml. These results suggest that proteins in \textit{B. cepacia} OMVs are not responsible for host cell cytotoxicity, but are responsible for pro-inflammatory responses in A549 cells.

DISCUSSION

\textit{B. cepacia} ATCC 25416 and two clinical isolates, P1311 and P1383, produced OMVs during \textit{in vitro} culture (20). These \textit{B. cepacia} OMVs induced the host cell cytotoxicity and the expression of pro-inflammatory cytokine and chemokine genes in lung epithelial cells, but specific molecules or components associated with the host cell pathology have not been determined. In the present study, we analyzed the proteomes of OMVs isolated from \textit{B. cepacia} ATCC 25416 and investigated the contribution of OMV proteins to pro-inflammatory responses \textit{in vitro}. The present study demonstrated that \textit{B. cepacia} OMVs contained 256 proteins derived from all bacterial compartments, and that proteins in OMVs were directly responsible for pro-inflammatory responses \textit{in vitro}.

Gram-negative, non-fermenting bacterial pathogens, including \textit{B. pseudomallei} (28), \textit{B. mallei} (29), \textit{P. aeruginosa} (15), \textit{A. baumannii} (16), \textit{A. nosocomialis} (17), and \textit{S. maltophilia} (18), produced OMVs. OMVs derived from gram-negative, non-fermenting pathogens induced host cell cytotoxicity and pro-inflammatory responses. In addition, \textit{B. cepacia} OMVs induced the cytotoxicity in A549 cells (20), but only < 20% of cells died at 20 μg/ml protein concentrations of \textit{B. cepacia} OMVs, suggesting that \textit{B. cepacia} OMVs are cytotoxic to host cells. Azurin homologue and hemolysin were found to be cytotoxic among the secretomes produced by BCC bacteria (30, 31), but proteomic analysis revealed that azurin, azurin homologues, and hemolysin were not identified in \textit{B. cepacia} OMVs in this study. Moreover, there was no significant difference in host cell cytotoxicity between intact OMVs and proteinase K-treated OMVs, indicating that non-protein components in \textit{B. cepacia} OMVs may be responsible for the host cell cytotoxicity. Instead, the present study identified several putative virulence-associated proteins in \textit{B. cepacia} OMVs. Although \textit{B. cepacia} OMVs are not highly cytotoxic to host cells, it is necessary to clarify cytotoxic factors in \textit{B. cepacia} OMVs for the development of OMV vaccines against \textit{B. cepacia}.

We previously demonstrated that OMVs derived from \textit{B. cepacia} ATCC 25416 induced the expression of pro-inflammatory cytokine genes, including \textit{IL1B}, \textit{IL6}, \textit{IL8}, \textit{TNF}, and \textit{CCL2}, in A549 cells, and also induced expression of \textit{IL1B}, \textit{IL6}, \textit{CXCL1P1}, \textit{TNF}, and \textit{CCL2} genes in the lungs of mice injected with \textit{B. cepacia} OMVs (20). Consistent with the previous study, the present study also showed that OMVs derived from \textit{B. cepacia} ATCC 25416 induced the expression of pro-inflammatory cytokine and chemokine genes in A549 cells. However, expression of \textit{IL1B}, \textit{IL6}, \textit{IL8}, and \textit{CCL2} genes was completely inhibited in A549 cells incubated with proteinase K-treated \textit{B. cepacia} OMVs (Fig. 2). These results suggest that proteins packaged in \textit{B. cepacia} OMVs are associated with the expression of these cytokine genes. In the present study, we did not determine the specific proteins associated with pro-inflammatory responses in \textit{B. cepacia} OMVs. However, our study demonstrates that proteins in \textit{B. cepacia} OMVs are potent pathogen-associated molecular patterns to stimulate pro-inflammatory responses \textit{in vitro}. The proteomic analysis of OMVs and the contribution of OMV proteins to host cell pathology may improve our understanding of \textit{B. cepacia} pathogenesis.
ACKNOWLEDGEMENTS

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (NRF-2020R1A2B5B01002228).

CONFLICT OF INTEREST

Authors declare no conflict of interests in this paper

REFERENCES

1) Lipuma JJ. Update on the *Burkholderia cepacia* complex. *Curr Opin Pulm Med* 2005;11:528-33.
2) Bach E, Sant’Anna FH, Magrich dos Passos JF, Balsanelli E, de Baura VA, Pedrosa FO, et al. Detection of misidentifications of species from the *Burkholderia cepacia* complex and description of a new member, the soil bacterium *Burkholderia catarinensis* sp nov. *Pathog Dis* 2017;75.
3) Kidd TJ, Douglas JM, Bergh HA, Coulter C, Bell SC. *Burkholderia cepacia* complex epidemiology in persons with cystic fibrosis from Australia and New Zealand. *Res Microbiol* 2008;159:194-9.
4) Kenna DTD, Lilley D, Coward A, Martin K, Perry C, Pike R, et al. Prevalence of *Burkholderia* species, including members of *Burkholderia cepacia* complex, among UK cystic and non-cystic fibrosis patients. *J Med Microbiol* 2017;66:490-501.
5) Burkholder WH. Sour skin, a bacterial rot of onion bulbs. *Phytopathology* 1950;40:115-7.
6) Abdelfattah R, Al-Jumaah S, Al-Qahtani A, Al-Thawadi S, Barron I, Al-Mofada S, et al. Outbreak of *Burkholderia cepacia* bacteraemia in a tertiary care centre due to contaminated ultrasound probe gel. *J Hosp Infect* 2018;98:289-94.
7) Abdallah M, Abdallah HA, Memish ZA. *Burkholderia cepacia* complex outbreaks among non-cystic fibrosis patients in the intensive care units: A review of adult and pediatric literature. *Infez Med* 2018;26:299-307.
8) Tegos GP, Haynes MK, Schweizer HP. Dissecting novel virulent determinants in the *Burkholderia cepacia* complex. *Virulence* 2012;3:234-7.
9) Thomson ELS, Dennis JJ. A *Burkholderia cepacia* complex non-ribosomal peptide-synthesized toxin is hemolytic and required for full virulence. *Virulence* 2012;3:286-98.
10) Lagatolla C, Skerlavaj S, Dolzani L, Tonin EA, Bragadin CM, Bosco M, et al. Microbiological characterization of *Burkholderia cepacia* isolates from cystic fibrosis patients: investigation of the exopolysaccharides produced. *FEMS Microbiol Lett* 2002;209:99-106.
11) Jan AT. Outer membrane vesicles (OMVs) of gram-negative bacteria: a perspective update. *Front Microbiol* 2017;8:1053.
12) Kulp A, Kuehn MJ. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. *Ann Rev Microbiol* 2010;64:163-84.
13) Ellis TN, Kuehn MJ. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. *Microbiol Mol Biol Rev* 2010;74:81-94.
14) Lee EY, Bang JY, Park GW, Choi DS, Kang JS, Kim HJ, et al. Global proteomic profiling of native outer membrane vesicles derived from *Escherichia coli*. *Proteomics* 2007;7:3143-53.

15) Bomberger JM, Maceachran DP, Coutermash BA, Ye S, O'Toole GA, Stanton BA. Long-distance delivery of bacterial virulence factors by *Pseudomonas aeruginosa* outer membrane vesicles. *PLoS Pathog* 2009;5:e1000382.

16) Jin JS, Kwon SO, Moon DC, Gurung M, Lee JH, Kim SI, et al. *Acinetobacter baumannii* secretes cytotoxic outer membrane protein A via outer membrane vesicles. *PLoS One* 2011;6:e17027.

17) Nho JS, Jun SH, Oh MH, Park TI, Choi CW, Kim SI, et al. *Acinetobacter nosocomialis* secretes outer membrane vesicles that induce epithelial cell death and host inflammatory responses. *Microb Pathog* 2015;81:39-45.

18) Kim YJ, Jeon H, Na SH, Kwon HI, Selasi GN, Nicholas A, et al. *Stenotrophomonas maltophilia* outer membrane vesicles elicit a potent inflammatory response *in vitro* and *in vivo*. *Pathog Dis* 2016;74:ftw104.

19) Allan ND, Kooi C, Sokol PA, Beveridge TJ. Putative virulence factors are released in association with membrane vesicles from *Burkholderia cepacia*. *Can J Microbiol* 2003;49:613-24.

20) Kim SY, Kim MH, Son JH, Kim SI, Yun SH, Kim K, et al. Outer membrane vesicles produced by *Burkholderia cepacia* cultured with subinhibitory concentrations of ceftazidime enhance pro-inflammatory responses. *Virulence* 2020;11:995-1005.

21) Yun SH, Park EC, Lee SY, Lee H, Choi CW, Yi YS, et al. Antibiotic treatment modulates protein components of cytotoxic outer membrane vesicles of multidrug-resistant clinical strain, *Acinetobacter baumannii* DU202. *Clin Proteomics* 2018;15:28.

22) Jeon H, Oh MH, Jun SH, Kim SI, Choi CW, Kwon HI, et al. Variation among *Staphylococcus aureus* membrane vesicle proteomes affects cytotoxicity of host cells. *Microb Pathog* 2016;93:185-93.

23) Kwon SO, Gho YS, Lee JC, Kim SI. Proteome analysis of outer membrane vesicles from a clinical *Acinetobacter baumannii* isolate. *FEMS Microbiol Lett* 2009;297:150-6.

24) Choi CW, Park EC, Yun SH, Lee SY, Lee YG, Hong Y, et al. Proteomic characterization of the outer membrane vesicle of *Pseudomonas putida* KT2440. *J Proteome Res* 2014;13:4298-309.

25) Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. *Mol Cell Proteomics* 2005;4:1265-72.

26) Van Faassen H, KuoLee R, Harris G, Zhao X, Conlan JW, Chen W. Neutrophils play an important role in host resistance to respiratory infection with *Acinetobacter baumannii* in mice. *Infect Immun* 2007;75:5597-608.

27) Jun SH, Lee JH, Kim BR, Kim SI, Park TI, Lee JC, et al. *Acinetobacter baumannii* outer membrane vesicles elicit a potent innate immune response via membrane proteins. *PLoS One* 2013;8:e71751.

28) Nieves W, Petersen H, Judy BM, Blumentritt CA, Russell-Lodrigue K, Roy CJ, et al. A *Burkholderia pseudomallei* outer membrane vesicle vaccine provides protection against lethal sepsis. *Clin Vaccine Immunol* 2014;21:747-54.

29) Norris MH, Khan MSR, Chirakul S, Schweizer HP, Tuanyok A. Outer membrane vesicle vaccines from biosafe surrogates prevent acute lethal glanders in mice. *Vaccines* 2018;6:5.

30) Punj V, Sharma R, Zaborina O, Chakrabarty AM. Energy-generating enzymes of *Burkholderia cepacia* and their interactions with macrophages. *J Bacteriol* 2003;185:3167-78.

31) Hutchison ML, Paxton IR, Govan JR. *Burkholderia cepacia* produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes. *Infect Immun* 1998;66:2033-9.